https://assets.capyfin.com/instruments/678fdc13234e27009c5d5fd6.png avatar
Maravai
🇺🇸 NASDAQ:MRVI
View Company
OverviewEarningsDividends
•
Dec 31, 2023

Maravai Q4 2023 Earnings Report

Reported financial results showing a decrease in revenue compared to the same period in the previous year, influenced by reduced COVID-19 related revenue and challenging industry conditions.

Key Takeaways

Maravai LifeSciences reported a Q4 2023 revenue of $74.1 million, a net loss of $(110.0) million, and an adjusted EBITDA margin of 28%. The revenue decrease was primarily driven by a significant decline in Nucleic Acid Production revenue, including COVID-19 related CleanCap revenue. The company is focusing on expanding its product portfolio and market leadership.

Q4 revenue was $74.1 million, a 64% decrease year-over-year.

Net loss for Q4 was $(110.0) million, compared to net income of $87.4 million in the same period last year.

Adjusted EBITDA margin for Q4 was 28%.

Full year 2024 revenue guidance is projected to be in the range of $265.0 million to $285.0 million.

Total Revenue
$74.1M
Previous year: $205M
-63.8%
EPS
$0.01
Previous year: $0.35
-97.1%
Gross Profit
$39M
Previous year: $151M
-74.2%
Cash and Equivalents
$575M
Previous year: $632M
-9.0%
Free Cash Flow
-$9.01M
Previous year: $93.1M
-109.7%
Total Assets
$1.49B
Previous year: $2.28B
-34.8%

Maravai

Maravai

Maravai Revenue by Segment

Forward Guidance

Maravai projects revenue for 2024 to be in the range of $265.0 million to $285.0 million, with adjusted EBITDA margins expected to be in the range of 23% to 25%.

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Company Overview

Full financial data and analysis

View Maravai